Adults with X-linked hypophosphatemia (XLH) would benefit from treatment programs that include primary care physicians, physical and occupational therapists, and social workers, according to a recent report. The study, “Osteoarthritis, Osteophytes and Enthesophytes Affect Biomechanical Function in Adults with X-linked Hypophosphatemia,” was published in …
Teeth problems associated with X-linked hypophosphatemia (XLH) are characterized by poor mineralization of several tooth tissues and jawbones, as well as defective mechanical properties, a study in mice suggests. The study, “Dentoalveolar Defects in the…
The U.S. Food and Drug Administration (FDA), a vast government bureaucracy, employs about 17,500 people and had a budget of $5.7 billion in 2019. Yet even with its enormous resources, the FDA these days relies more and more on patients to…
The gleaming new Dutch headquarters of the European Medicines Agency (EMA), fronting Domenico Scarlattilaan in Amsterdam’s suburban Zuidas business district, finally opened for business last month — just over two years after the European Union decided to relocate the EMA to the Netherlands in the wake of Brexit.
While conventional treatment combining phosphate supplementation with active vitamin D is effective for a large number of people with X-linked hypophosphatemia (XLH), some patients develop treatment-associated complications or fail to respond, a review study reports. In these cases, considerable hope is being placed on treatment with Crysvita (burosumab),…
A mutation in a region of the PHEX gene — a region containing no information to make proteins — leads to mild X-linked hypophosphatemia (XLH), especially in females, compared to variants in other regions of the same gene, researchers have found. This finding presents challenges for diagnosis and…
Approximately one third of children and young adults with X‐linked hypophosphatemia (XLH) are overweight or obese, a study has found. Lack of family history of XLH and longer treatment with phosphorus supplements were identified as risk factors for excessive weight gain in these patients. The study, “…
The burden of X-linked hypophosphatemia (XLH) is centered on treatment in childhood, expands to psychological impact and other factors in adolescence, and shifts in adulthood to the need for other interventions and mobility, a study reports. These findings, which were based on responses primarily from patients and caregivers in…
If combined with an approach that targets hallmark abnormalities in X-linked hypophosphatemia (XLH), treatment with growth hormone could normalize bone growth and structure in these patients, a study in mice suggests. The study, “MAPK inhibition and growth hormone: a promising therapy in XLH,” was published…
Treatment with Crysvita (burosumab) restores phosphate balance and improves bone mineralization in adults with X‐linked hypophosphatemia (XLH), a Phase 3 trial shows. The findings were reported in a study, “Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X‐Linked Hypophosphatemia: A Phase 3, Single‐Arm,…
Get regular updates to your inbox.